Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
Open Access
- 15 January 2012
- journal article
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 4 (1) , e2012035
Abstract
Introduction: Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m2 administered on days 1,4,8 and 11 of a 21 day cycle), with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM).Methods: We treated a MM patient with Cystic Fibrosis with Bortezomib alone to avoid the use of corticosteroid and consequently the risk of lung infection reactivations, first of all due to the patient Pseudomonas aeruginosa colonization. Bortezomib was administrated at 1.3 mg/m2 on days 1,4,8 and 11 with a 10 day rest period and four 21-day cycles were administered. We evaluate the treatment response and toxicity.Results: After four cycles of therapy the patient achieved a very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects.Conclusions: Bortezomib can be successfully utilized for the management of this difficult disease situationKeywords
This publication has 12 references indexed in Scilit:
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010
- VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA StudyJournal of Clinical Oncology, 2009
- The proteostasis boundary in misfolding diseases of membrane trafficFEBS Letters, 2009
- Dislipidemia relacionada à fibrose císticaJornal Brasileiro de Pneumologia, 2008
- Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patientsBMC Musculoskeletal Disorders, 2008
- Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐upBritish Journal of Haematology, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003